70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas

Plus readouts from Genmab, AstraZeneca, Merck, Astellas and more

J&J to bring Rybrevant into two Phase III colorectal cancer studies based on Phase II data

Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions

CEO Jeremy Bender on building a strategy for pediatric cancer therapies that serves both patients and investors 

Day One, X4 and ImmunityBio each received their first drug approvals 

No black box warning and a broad label for the pediatric brain cancer therapy

Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen 

Therapy will be made at the biotech’s Philadelphia facility and a nearby CDMO, with plans to serve ‘up to several thousand patients annually’

Five-year-old biotech receives April PDUFA date for pan-RAF inhibitor to treat slow-moving pediatric brain cancer